Back
Raymond James Financial Vs. Sarepta Therapeutics Industry Stock Comparison
Buy
72
RJF
Raymond James Financial
Last Price:
170.13
Seasonality Move:
8.58%
Sell
49
SRPT
Sarepta Therapeutics
Last Price:
138.01
Seasonality Move:
14.88%
Buy
72
Raymond James Financial (RJF)
is a Buy
Is Raymond James Financial a Buy, Sell or Hold?
- The current Raymond James Financial [RJF] share price is $168.92. The Score for RJF is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.
- RJF is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
49
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
RJF Stock Price Chart
What is Raymond James Financial's stock price today?
-
The Raymond James Financial share price today is $168.92
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and RJF is experiencing buying pressure, which is a positive indicator for future bullish movement.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $130.50
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
RJF Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 7.26 | Buy |
| Relative Strength Index (14 RSI): | 76.78 | Buy |
| Chaikin Money Flow: | 1154565 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (147.23 - 164.43) | Buy |
| Bollinger Bands (100): | (110.95 - 146.09) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -2.3 | Sell |
| Relative Strength Index (14 RSI): | 64.59 | Buy |
| Chaikin Money Flow: | 3149400 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (111.02 - 128.88) | Buy |
| Bollinger Bands (100): | (119.18 - 142.3) | Sell |
RJF Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 164.23 | Buy |
| 20-day SMA: | 158.45 | Buy |
| 50-day SMA: | 141.81 | Buy |
| 200-day SMA: | 125.48 | Buy |
| 8-day EMA: | 164.55 | Buy |
| 20-day EMA: | 158.34 | Buy |
| 50-day EMA: | 145.76 | Buy |
| 200-day EMA: | 126.92 | Buy |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 112.07 | Buy |
| 20-day SMA: | 117.27 | Buy |
| 50-day SMA: | 121.92 | Buy |
| 200-day SMA: | 129.99 | Buy |
| 8-day EMA: | 116.28 | Buy |
| 20-day EMA: | 117.14 | Buy |
| 50-day EMA: | 121.91 | Buy |
| 200-day EMA: | 125.98 | Buy |
Raymond James Financial Earnings Growth & RJF Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.15 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.07 per share, and an increase next year of $0.90 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.
Raymond James Financial Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||